Clinical Uses of Botulinum Neurotoxins: Current Indications, Limitations and Future Developments
Open Access
- 18 October 2012
- Vol. 4 (10), 913-939
- https://doi.org/10.3390/toxins4100913
Abstract
Botulinum neurotoxins (BoNTs) cause flaccid paralysis by interfering with vesicle fusion and neurotransmitter release in the neuronal cells. BoNTs are the most widely used therapeutic proteins. BoNT/A was approved by the U.S. FDA to treat strabismus, blepharospam, and hemificial spasm as early as 1989 and then for treatment of cervical dystonia, glabellar facial lines, axillary hyperhidrosis, chronic migraine and for cosmetic use. Due to its high efficacy, longevity of action and satisfactory safety profile, it has been used empirically in a variety of ophthalmological, gastrointestinal, urological, orthopedic, dermatological, secretory, and painful disorders. Currently available BoNT therapies are limited to neuronal indications with the requirement of periodic injections resulting in immune-resistance for some indications. Recent understanding of the structure-function relationship of BoNTs prompted the engineering of novel BoNTs to extend therapeutic interventions in non-neuronal systems and to overcome the immune-resistance issue. Much research still needs to be done to improve and extend the medical uses of BoNTs.Keywords
This publication has 171 references indexed in Scilit:
- Insights into the Different Catalytic Activities of Clostridium NeurotoxinsBiochemistry, 2012
- The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: a systematic review and meta analysisInflammopharmacology, 2010
- Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trialZeitschrift für Neurologie, 2010
- Engineering botulinum neurotoxin to extend therapeutic interventionProceedings of the National Academy of Sciences, 2009
- Glycosylated SV2 and Gangliosides as Dual Receptors for Botulinum Neurotoxin Serotype FBiochemistry, 2009
- Receptor and substrate interactions of clostridial neurotoxinsToxicon, 2009
- Translocation of botulinum neurotoxin light chain protease by the heavy chain protein-conducting channelToxicon, 2008
- Identification of Residues Surrounding the Active Site of Type A Botulinum Neurotoxin Important for Substrate Recognition and Catalytic ActivityProtein Journal, 2008
- Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor conceptProceedings of the National Academy of Sciences, 2007
- SNAREs — engines for membrane fusionNature Reviews Molecular Cell Biology, 2006